Project Group Developmental Therapeutics
On November 22, 2019, the members of the SAKK Project Group New Anticancer Treatments and the SAKK Working Groups Immuno-Oncology and Molecular Oncology decided to merge and become the new Project Group Developmental Therapeutics (PG DT). This merger will allow us to make optimal use of the expertise of all members, to have strong trials in the immunotherapy and non-immunotherapy fields, potential combinations between the two, and strong translational programs.
By that, the new PG DT will have a broadened focus on innovation in oncology as well as an increased member base.
Please find the current projects here.